2026 Q1 Portfolio Activity
In 2026 Q1, ACORN CAPITAL ADVISORS, LLC maintained a portfolio of 23 distinct positions. The most significant new addition was JADE BIOSCEINCES INC, now representing 3.14% of the total fund value. They heavily accumulated shares in LEONABIO, INC., increasing the position by 26.5%. The fund also reduced its exposure to JASPER THERAPEUTICS by 21.0%.
Position History
hover any row below to update
Loading…
Total Positions
23
Quarter
2026 Q1
Top Holding
TERN (26.2%)
Top 10 Concentration
88.9%
Turnover Rate
23.4%
Sector HHI
0.18
Items per page:
Showing 1-23 of 23
ACORN CAPITAL ADVISORS, LLC Full Holdings List — 2026 Q1
| Stock | History | Sector / Type | Port % | Prev % | Rank / Prev | Conviction | Change | % Change | Influence | Shares | Mkt Value | Avg Cost | Price Held | 1st Owned | Source | Source Date | Date Reported | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
TERN
TERNS PHARMACEU...
|
Healthcare | 26.17% | 23.90% |
#1
Prev: #1
|
7.0 |
—
|
no change | no change |
P
S
|
1,746,264 | $92,063,038 | 2024 Q4 | 13F Filing | 2026-03-31 | 2026-05-15 | |||
|
CGON
CG ONCOLOGY INC
|
Healthcare | 21.77% | 15.92% |
#2
Prev: #2
|
6.0 |
—
|
-1,000 | -0.1% |
P
S
|
1,130,501 | $76,579,958 | 2024 Q4 | 13F Filing | 2026-03-31 | 2026-05-15 | |||
|
URGN
UROGEN PHARMA L...
|
Healthcare | 8.55% | 11.49% |
#3
Prev: #3
|
6.4 |
—
|
225,000 | 15.5% |
P
S
|
1,673,420 | $30,088,092 | 2024 Q4 | 13F Filing | 2026-03-31 | 2026-05-15 | |||
|
PBYI
PUMA BIOTECHNOL...
|
Healthcare | 7.50% | 8.33% |
#4
1
Prev: #5
|
4.5 |
—
|
no change | no change |
P
S
|
4,131,299 | $26,399,001 | 2024 Q4 | 13F Filing | 2026-03-31 | 2026-05-15 | |||
|
TRVI
TREVI THERAPEUT...
|
Healthcare | 7.27% | 9.10% |
#5
1
Prev: #4
|
4.4 |
—
|
no change | no change |
P
S
|
2,144,844 | $25,587,989 | 2024 Q4 | 13F Filing | 2026-03-31 | 2026-05-15 | |||
|
CADL
CANDEL THERAPEU...
|
Healthcare | 4.89% | 4.94% |
#6
Prev: #6
|
4.5 |
—
|
917,431 | 35.6% |
P
S
|
3,497,948 | $17,209,904 | 2024 Q4 | 13F Filing | 2026-03-31 | 2026-05-15 | |||
|
BCAX
BICARA THERAPEU...
|
Healthcare | 3.64% | 3.67% |
#7
2
Prev: #9
|
2.5 |
—
|
no change | no change |
P
S
|
643,382 | $12,796,860 | 2024 Q4 | 13F Filing | 2026-03-31 | 2026-05-15 | |||
|
OKUR
ONKURE THERAPEU...
|
Healthcare | 3.34% | 2.79% |
#8
3
Prev: #11
|
2.3 |
—
|
no change | no change |
P
S
|
2,839,674 | $11,756,250 | 2024 Q4 | 13F Filing | 2026-03-31 | 2026-05-15 | |||
|
JBIO
JADE BIOSCEINCE...
|
Healthcare | 3.14% | — |
#9
Prev: #—
|
4.8 |
—
|
786,760 | — |
NEW
|
786,760 | $11,053,978 | 2026 Q1 | 13F Filing | 2026-03-31 | 2026-05-15 | |||
|
TARA
PROTARA THERAPE...
|
Healthcare | 2.59% | 3.16% |
#10
Prev: #10
|
2.0 |
—
|
no change | no change |
P
S
|
1,752,115 | $9,128,519 | 2024 Q4 | 13F Filing | 2026-03-31 | 2026-05-15 | |||
|
VSTM
VERASTEM INC
|
Healthcare | 2.21% | 3.84% |
#11
3
Prev: #8
|
1.9 |
—
|
no change | no change |
P
S
|
1,469,153 | $7,786,511 | 2025 Q1 | 13F Filing | 2026-03-31 | 2026-05-15 | |||
|
CYBN
HELUS PHARMA IN...
|
Unknown | 2.10% | 4.36% |
#12
5
Prev: #7
|
1.3 |
—
|
-32,757 | -2.1% |
P
S
|
1,540,266 | $7,393,277 | 2024 Q4 | 13F Filing | 2026-03-31 | 2026-05-15 | |||
|
LONA
LEONABIO, INC.
|
Healthcare | 1.85% | 1.29% |
#13
Prev: #13
|
3.2 |
—
|
132,800 | 26.5% |
P
S
|
634,539 | $6,523,061 | 2025 Q4 | 13F Filing | 2026-03-31 | 2026-05-15 | |||
|
AURA
AURA BIOSCIENCE...
|
Healthcare | 1.13% | 1.10% |
#14
1
Prev: #15
|
1.5 |
—
|
no change | no change |
P
S
|
595,744 | $3,985,527 | 2025 Q1 | 13F Filing | 2026-03-31 | 2026-05-15 | |||
|
WHWK
WHITEHAWK THERA...
|
Healthcare | 1.12% | 0.93% |
#15
1
Prev: #16
|
1.4 |
—
|
no change | no change |
P
S
|
1,139,363 | $3,930,802 | 2024 Q4 | 13F Filing | 2026-03-31 | 2026-05-15 | |||
|
CRDF
CARDIF ONCOLOGY...
|
Healthcare | 0.81% | 1.87% |
#16
4
Prev: #12
|
0.8 |
—
|
-200,000 | -10.2% |
P
S
|
1,762,084 | $2,854,576 | 2024 Q4 | 13F Filing | 2026-03-31 | 2026-05-15 | |||
|
QTTB
Q32 BIO INC.
|
Healthcare | 0.57% | 0.56% |
#17
1
Prev: #18
|
0.2 |
—
|
-178,373 | -36.1% |
P
S
|
315,052 | $2,022,634 | 2024 Q4 | 13F Filing | 2026-03-31 | 2026-05-15 | |||
|
KPTI
KARYOPHARM THER...
|
Healthcare | 0.46% | — |
#18
Prev: #—
|
3.7 |
—
|
287,826 | — |
NEW
|
287,826 | $1,603,191 | 2026 Q1 | 13F Filing | 2026-03-31 | 2026-05-15 | |||
|
JSPR
JASPER THERAPEU...
|
Healthcare | 0.35% | 1.11% |
#19
5
Prev: #14
|
0.1 |
—
|
-375,000 | -21.0% |
P
S
|
1,411,492 | $1,242,113 | 2025 Q3 | 13F Filing | 2026-03-31 | 2026-05-15 | |||
|
N/A
X4 PHARMACEUTIC...
|
|
Unknown | 0.27% | 0.37% |
#20
1
Prev: #19
|
0.6 |
—
|
-39,310 | -14.4% |
P
S
|
234,039 | $966,583 | — | 13F Filing | 2026-03-31 | 2026-05-15 | ||
|
BCAB
BIOATLA INC
|
Healthcare | 0.25% | 0.93% |
#21
4
Prev: #17
|
2.1 |
—
|
571,234 | 11.8% |
P
S
|
5,406,345 | $865,015 | 2024 Q4 | 13F Filing | 2026-03-31 | 2026-05-15 | |||
|
VYNE
VYNE THERAPEUTI...
|
Healthcare | 0.00% | 0.00% |
#22
1
Prev: #21
|
1.0 |
—
|
no change | no change |
P
S
|
1,425 | $855 | 2024 Q4 | 13F Filing | 2026-03-31 | 2026-05-15 | |||
|
ACRV
ACRIVON THERAPE...
|
Healthcare | 0.00% | 0.33% |
Sold All 😨
(Was: #20) |
0.0 |
—
|
-405,237 | -100.0% |
CLOSED
|
— | $— | 2024 Q4 | 13F Filing | 2026-03-31 | 2026-05-15 |
Showing 1-23 of 23 holdings